Vyaderm Pharmaceuticals: The EVA Decision Custom Case Solution & Analysis

Evidence Brief: Vyaderm Pharmaceuticals

1. Financial Metrics

Total Corporate Revenue: 2.6 billion dollars in 1999.
Cost of Capital: Vyaderm uses a 10 percent weighted average cost of capital (WACC) for internal evaluations.
Dermatology Division: 1.1 billion dollars in sales; 155 million dollars in operating profit; 450 million dollars in total assets.
Agriculture Division: 700 million dollars in sales; 24 million dollars in operating profit; 550 million dollars in total assets.
Generics Division: 800 million dollars in sales; 62 million dollars in operating profit; 320 million dollars in total assets.
Project 2000 (Dermatology): Proposed 8 million dollar marketing investment expected to yield 12 million dollars in incremental profit over two years.
Bonus System: Current bonuses capped at 25 percent of base salary; tied to budget-based targets.

2. Operational Facts

Structure: Three primary divisions with distinct market dynamics: Dermatology (branded, high margin), Generics (commodity, high volume), and Agriculture (cyclical, low margin).
Investment Process: Capital requests exceeding 5 million dollars require corporate approval; smaller amounts handled at the divisional level.
R and D Accounting: Currently expensed as incurred, following standard GAAP procedures.
Incentive Culture: Managers historically focused on meeting annual budget targets rather than long term value creation.

3. Stakeholder Positions

Maurice Richardson (CEO): Advocate for Economic Value Added (EVA) to align manager interests with those of shareholders.
Thomas (CFO): Responsible for technical implementation of the EVA formula and adjusting for accounting distortions.
Dermatology Head: Concerned that EVA will penalize necessary brand building investments like Project 2000.
Agriculture Head: Worried that high capital intensity in a low margin business will result in negative EVA and zero bonuses.
Generics Head: Views EVA as a tool to justify capacity expansion if volume growth offsets capital charges.

4. Information Gaps

Historical R and D spending levels for the past five years are not provided, making immediate capitalization calculations difficult.
Specific tax rates for different global jurisdictions are omitted.
The exact duration of the bonus bank vesting period is not defined in the initial proposal.
Competitor incentive structures are mentioned generally but lack specific data for benchmarking.

Strategic Analysis

1. Core Strategic Question

How can Vyaderm implement a value based management system that incentivizes capital efficiency without discouraging the long term investments required for pharmaceutical innovation?

2. Structural Analysis

Capital Allocation Distortion: The current GAAP based reporting treats R and D and marketing as expenses. This creates a structural bias toward short term profit at the expense of future growth. Under EVA, these must be treated as capital assets to prevent managers from cutting innovation to meet quarterly targets.
Divisional Heterogeneity: The Agriculture division is structurally different from Dermatology. Agriculture is capital heavy and low margin. Applying a uniform 10 percent capital charge without adjusting for the specific risk profile or asset age will lead to immediate morale failure in the Agriculture unit.
Incentive Misalignment: The existing 25 percent bonus cap encourages sandbagging during budget negotiations. If a manager exceeds the target significantly, they receive no extra reward, leading to the deferral of gains to the next fiscal year.

3. Strategic Options

Option A: Pure EVA Implementation. Apply standard EVA (NOPAT minus 10 percent capital charge) across all units with no accounting adjustments.

Rationale: Maximum transparency and simplicity.
Trade-offs: Disproportionately punishes Dermatology for R and D and Agriculture for its asset base.
Requirements: Minimal accounting changes; high risk of managerial turnover.

Option B: Tailored EVA with Capitalized Intangibles. Capitalize R and D and major marketing campaigns (like Project 2000) over a five year period.

Rationale: Aligns the metric with the actual economic life of pharmaceutical assets.
Trade-offs: Increases complexity and requires subjective decisions on what qualifies for capitalization.
Requirements: Significant audit of historical R and D spending.

Option C: Hybrid Performance Framework. Use EVA for the Generics and Agriculture units but maintain a balanced scorecard for Dermatology.

Rationale: Recognizes that different business models require different incentives.
Trade-offs: Creates internal inequity and complicates corporate wide performance comparisons.
Requirements: Two separate incentive systems managed by HR.

4. Preliminary Recommendation

Pursue Option B. Vyaderm must capitalize R and D and strategic marketing. Without this adjustment, the Dermatology division—the primary growth engine—will be incentivized to liquidate its future to pay for its current capital charge. The bonus bank must also be implemented to ensure that gains are sustained over time before being paid out.

Implementation Roadmap

1. Critical Path

Month 1: Data Normalization. Reconstruct the last five years of financial statements to capitalize R and D and marketing expenses. This establishes the true starting capital base.
Month 2: Baseline Setting. Calculate the EVA for each division over the last three years to set realistic improvement targets. Avoid using the current budget as the baseline.
Month 3: Education and Training. Conduct intensive workshops for the top 150 managers to explain the math behind the capital charge.
Month 4: Parallel Run. Track both the old budget system and the new EVA system for one quarter to identify unintended consequences.

2. Key Constraints

Data Integrity: The accuracy of the R and D amortization schedule is the most likely point of failure. If managers perceive the capitalization period as arbitrary, they will reject the system.
Agriculture Morale: The Agriculture division will likely start with negative EVA. Management must decide whether to grant an initial EVA interval or target a reduction in negative EVA rather than an absolute positive number.

3. Risk-Adjusted Implementation Strategy

The implementation will use a bonus bank mechanism. One third of any bonus earned will be paid out annually, with two thirds remaining at risk in the bank. If EVA turns negative in future years, the bank is reduced. This mitigates the risk of managers gaming the system for a one year windfall. To account for local market nuance, the capital charge for Agriculture should be reviewed against industry specific asset turnover rates to ensure the division remains competitive for internal funding.

Executive Review and BLUF

1. BLUF

Adopt the EVA framework immediately but reject the unadjusted GAAP model. To protect the future of the Dermatology division, R and D and strategic marketing must be capitalized and amortized over five years. The current 25 percent bonus cap must be eliminated in favor of an uncapped bonus bank system. This shift moves management focus from budget negotiation to genuine economic profit. Agriculture requires a separate capital charge baseline to prevent immediate divestiture of essential assets. Without these specific adjustments, EVA will trigger a cycle of underinvestment that will erode the competitive position of the branded drug portfolio within three years.

2. Dangerous Assumption

The analysis assumes that divisional managers possess the operational autonomy to significantly alter their capital employment. In a highly regulated pharmaceutical environment, much of the capital is trapped in fixed facilities and long term clinical trials that managers cannot exit quickly, regardless of the incentive structure.

3. Unaddressed Risks

Tax Inefficiency: The plan focuses on NOPAT but does not address how EVA targets will interact with global transfer pricing strategies, potentially creating a conflict between tax optimization and divisional bonus targets. (Probability: High; Consequence: Moderate).
Talent Attrition: Managers in the Agriculture division may see the 10 percent capital charge as an insurmountable hurdle and seek employment at competitors with traditional bonus structures. (Probability: Medium; Consequence: High).

4. Unconsidered Alternative

The team failed to consider a staged divestiture of the Agriculture division prior to EVA implementation. If the unit cannot meet the cost of capital, the most value creative move may be a sale to a specialized agribusiness where the assets would have a lower cost of capital, rather than attempting an internal turnaround under a new accounting regime.